翰森製藥(03692.HK)與Silence Therapeutics訂立獨家許可合作協議
格隆匯10月15日丨翰森製藥(03692.HK)發佈公吿,2021年10月15日,公司已與Silence Therapeutics plc(AIM:SLN和納斯達克代碼:SLN)訂立獨家許可合作協議。根據許可協議,公司及Silence Therapeutics將利用Silence Therpaeutics的獨家mRNAi GOLD™平台,以合作開發針對三個靶點的siRNA(短干擾RNA)。對於首兩個靶點,在完成一期臨牀研究後,公司將擁有在中國(包括中國香港、中國澳門及中國台灣)的許可的獨家選擇權,而Silence Therapeutics將擁有該地域以外其他地區的獨家權益。Silence Therapeutics將負責許可權行使之前的所有活動,並將對該地域以外的首兩個靶點的一期臨牀後開發負責。對於第三個靶點,公司將於新藥臨牀試驗(IND)申報時獲得全球權利許可的獨家選擇權。公司將負責第三個靶點選擇權行使後的所有開發活動。
Silence Therapeutics將從公司獲得1600萬美元的預付款,並在達到額外的開發、監管和商業里程碑後合資格獲得高達13億美元。Silence Therapeutics也將獲得公司產品淨銷售額約10%到15%區間的特許權使用費。憑藉Silence Therapeutics在siRNA治療開發方面的領先地位及其數十年的科學和技術經驗,公司看到Silence Therapeutics的mRNAi GOLD™平台為中國和全球的患者開發和帶來更好的精準藥物的巨大機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.